Previous close | 6.86 |
Open | 6.00 |
Bid | 4.70 |
Ask | 5.80 |
Strike | 185.00 |
Expiry date | 2025-01-17 |
Day's range | 5.65 - 6.00 |
Contract range | N/A |
Volume | |
Open interest | 1.24k |
AbbVie (ABBV) closed the most recent trading day at $196.42, moving +1.56% from the previous trading session.
AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased at the upcoming European Society for Medical Oncology (ESMO) Congress 2024 (September 13-17, 2024). Presentations include data on mirvetuximab soravtansine (ELAHERE®) and c-Met targeting ADCs, telisotuzumab vedotin (Teliso-V) and telisotuzumab adizutecan (ABBV-400). AbbVie's ADCs are designed to target protein biomarkers such as folate receptor-alpha (FRα) and c-Met (MET
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.